Navigation Links
Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Date:9/4/2009

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl). The FDA informed Takeda on June 26, 2009 that further review of the alogliptin monotherapy NDA would be conditional based upon additional data from a cardiovascular (CV) safety study that satisfies the statistical requirements of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes."

"This complete response letter from the FDA is consistent with the June 26 complete response letter for alogliptin, a key component of the alogliptin and ACTOS fixed-dose combination product," said Nancy Joseph-Ridge, M.D., general manager, Pharmaceutical Development Division. "The FDA recently agreed to the study design for a cardiovascular outcomes trial for alogliptin, titled EXAMINE, and patient enrollment is planned to begin this month. We anticipate that the EXAMINE trial will provide the FDA with the information needed to continue the NDA reviews of both the alogliptin monotherapy and the alogliptin and ACTOS fixed-dose combination."

The complete response letter was specific to the FDC of alogliptin and ACTOS, and did not include any new questions or concerns about alogliptin or ACTOS.

About ACTOS(R) (pioglitazone HCl)

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diab
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
2. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
3. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
4. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
5. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
6. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
7. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
8. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
10. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... a.m. EDT-, MONTVALE, N.J., Oct. 15 ... top-line data from the,multi-center, randomized, double-blind, placebo-controlled Phase ... channel modulator, in Alzheimer,s,disease. The trial enrolled 183 ... 40 centers in the United States and included ...
... Fla., Oct. 13 Acutely ill, hospitalized,patients ... taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared,to ... with INVEGA as early as five days ... the two-week study period, according to preliminary ...
Cached Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... for about half of all visits to psychotherapists, and ... with couples.// The therapist helps the couple work on ... perpetuate conflict, explains the March 2007 issue of the ... make little use of psychiatric diagnosis, but they do ...
... of breastfeeding outweigh the risks of virus transmission from HIV-positive ... African nations.// ,A study in Zambia showed ... breast milk ¯ beyond a set time period of ... The study was a collaboration between US universities and University ...
... shows that a form of vitamin A used to treat ... small molecules called microRNAs (miRNAs) in the// leukemic cells. ... miRNAs inhibit the action of two genes important for cancer ... ,The drug is called all-trans-retinoic acid (ATRA) and it ...
... of bioactive compounds in the blood and boost antioxidant ... start// to rival the juice for boosting health. ... rise, particularly in the UK where sales have rocketed ... the antioxidant-rich fruit that has commonly been linked to ...
... in Porirua is not linked to a cluster of cases ... have been treated for typhoid in Porirua and those cases ... of health, regional public health, Wellington, said last night. ... which was being treated very seriously. ,Two of ...
... According to a study published on bmj.com, the second born ... This study also states that there is no big// difference ... second twin born at or after the complete term of ... shortly after birth. ,Many studies have talked about ...
Cached Medicine News:Health News:Breastfeeding Benefits may Outweigh HIV Risk 2Health News:Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down 2Health News:Science Builds Behind Pomegranate Extracts for Health 2
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
... reliable system. Varian accelerators offers highest ... fastest beam-on times to full stability ... milliseconds, pulse-to-pulse beam control for dynamic ... of multileaf collimator (MLC) products that ...
Medicine Products: